Research Article
Increased Occurrence of Valproic Acid-Induced Hyperammonemia in Carriers of T1405N Polymorphism in Carbamoyl Phosphate Synthetase 1 Gene
Table 1
Demographic and clinical characteristics of Caucasian patients treated with valproic acid (VPA) enrolled into the study protocol.
| | | Pennsylvania cohort () | Warsaw cohort () | Combined () |
| | Minor allele (A) frequency in CPS1 4217C > A | 0.302 | 0.318 | 0.307 | | Number of carriers of the minor allele (%) | 50 (52%) | 23 (52%) | 73 (52%) | | Gender (F/M) | 49/48 | 22/23 | 71/71 | | Age (years) | | | | | Weight (kg) | | | | | Number of patients administered multiple antiepileptic drugs (%) | 56 (57.7%)* | 11 (24.4%) | 67 (47.2%) | | Number of subjects with hyperammonemia (>65 mol/L) (%) | 5 (5.2%) | 6 (13.3%) | 11 (7.7%) | | VPA dosage (mg/24 hrs) | | | | | Plasma VPA level | | | | | Aminotransferases (U/L): | | | | | AST | | | | | ALT | | | | | Blood ammonia level | | | | (mol/L): average ± SD,
median (interquartile range) and data range | 22 (19–29)*
113 | 37 ( 35–55)
162 | 24 (11–76)
175 |
|
|
by T test or by Mann-Whitney test for differences between investigated cohorts.
|
